Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
breast cancer
cost-effectiveness analysis
genetic testing
screening
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Apr 2022
06 Apr 2022
Historique:
received:
14
02
2022
revised:
29
03
2022
accepted:
30
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Unselected multigene testing for all women with breast cancer (BC) identifies more cancer susceptibility gene (CSG) carriers who can benefit from precision prevention compared with family history (FH)/clinical-criteria-based guidelines. Very little CSG testing is undertaken in middle-income countries such as China, and its cost-effectiveness remains unaddressed. We aimed to estimate cost-effectiveness and population impact of multigene testing for all Chinese BC patients. Data from 8085 unselected BC patients recruited to a Peking University Cancer Hospital study were used for microsimulation modeling, comparing three strategies in the Chinese setting: all BC women undergo
Identifiants
pubmed: 35406611
pii: cancers14071839
doi: 10.3390/cancers14071839
pmc: PMC8997428
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Natural Science Foundation of China
ID : 71911530221 and 72174010
Organisme : China Medical Board
ID : 19-336
Références
Value Health. 2003 Sep-Oct;6(5):551-9
pubmed: 14627061
J Community Genet. 2013 Jul;4(3):379-90
pubmed: 23595912
JAMA Oncol. 2022 Feb 17;:
pubmed: 35175286
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Obstet Gynecol. 2013 Apr;121(4):709-716
pubmed: 23635669
BJOG. 2012 Apr;119(5):527-36
pubmed: 22260402
Genet Med. 2020 Apr;22(4):681-685
pubmed: 31831881
MDM Policy Pract. 2019 Feb 01;4(1):2381468318821103
pubmed: 30746499
JAMA Oncol. 2019 Oct 03;:
pubmed: 31580391
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
Int J Cancer. 2008 May 1;122(9):2017-22
pubmed: 18196574
Value Health. 2005 Jan-Feb;8(1):1-2
pubmed: 15841888
PLoS One. 2013 Nov 20;8(11):e81055
pubmed: 24278375
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
J Natl Cancer Inst. 2015 Aug 11;107(9):
pubmed: 26264690
Menopause. 2009 Jan-Feb;16(1):15-23
pubmed: 19034050
Breast. 2013 Oct;22(5):561-8
pubmed: 23972475
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503154
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
Lancet Oncol. 2014 Jun;15(7):e279-89
pubmed: 24872111
JAMA. 2018 Sep 25;320(12):1266-1274
pubmed: 30264118
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
J Natl Cancer Inst. 2015 Mar 18;107(5):
pubmed: 25788320
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
BMC Cancer. 2011 Aug 22;11:364
pubmed: 21859480
Value Health. 2021 Feb;24(2):303-312
pubmed: 33518037
Crit Rev Oncol Hematol. 2018 Dec;132:138-144
pubmed: 30447919
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2318-24
pubmed: 19661091
Ann Surg Oncol. 2019 Oct;26(10):3025-3031
pubmed: 31342359
Nat Rev Genet. 2018 Apr;19(4):235-246
pubmed: 29353875
Ann Surg Oncol. 2021 Apr;28(4):2219-2226
pubmed: 32989658
Ann Surg Oncol. 2021 Sep;28(9):4967-4973
pubmed: 33761021
Arch Gerontol Geriatr. 2018 Nov - Dec;79:32-38
pubmed: 30086414
J Clin Oncol. 2020 Mar 1;38(7):674-685
pubmed: 31841383
Clin Breast Cancer. 2016 Dec;16(6):e165-e173
pubmed: 27544692
J Clin Oncol. 2019 May 20;37(15):1305-1315
pubmed: 30964716
Clin Cancer Res. 2017 Oct 15;23(20):6113-6119
pubmed: 28724667